Ito K, Mikamo H, Tamaya T, Yamada Y, Hayasaki M
Department of Obstetrics and Gynecology, School of Medicine, Gifu University.
Jpn J Antibiot. 1991 Jun;44(6):683-8.
Pharmacokinetic and clinical studies on flomoxef (FMOX) in the perinatal period were carried out. The results are summarized as follows. 1. The concentration of FMOX in umbilical cord serum was about 10 micrograms/ml in about 30 minutes after 1 g one shot intravenous injection. Amniotic fluid concentration was 7 micrograms/ml in 41 minutes after administration. By 1 hour intravenous drip infusion, FMOX concentration in umbilical cord serum was about 5 micrograms/ml in 2-3 hours after administration. Amniotic fluid concentration of about 20 micrograms/ml was found in 1 case. 2. FMOX 1-2 g x 2-3/day was given by intravenous drip infusion to 7 cases of perinatal infection for 4-26 days. Clinical efficacies were evaluated a good for all cases. Neither side effect nor abnormal laboratory test value was observed. Consequently, FMOX was considered to be highly effective and safe for its clinical use in perinatal period infections.
进行了氟氧头孢（FMOX）围产期的药代动力学和临床研究。结果总结如下。1. 单次静脉注射1g后约30分钟，脐血血清中氟氧头孢浓度约为10微克/毫升。给药后41分钟羊水浓度为7微克/毫升。通过1小时静脉滴注，给药后2 - 3小时脐血血清中氟氧头孢浓度约为5微克/毫升。1例羊水浓度约为20微克/毫升。2. 对7例围产期感染患者静脉滴注氟氧头孢1 - 2g×2 - 3次/天，持续4 - 26天。临床疗效评估为所有病例均良好。未观察到副作用或实验室检查值异常。因此，氟氧头孢在围产期感染的临床应用中被认为是高效且安全的。
